Superiority of Ga-68-FAPI-46 over F-18-FDG PET/CT in patients with solitary fibrous tumors (SFT)
Nuklearmedizin - NuclearMedicine · 01.04.2023 · 62 (02) · 121-122
DOI: 10.1055/s-0043-1766254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2023. Verfasst von K. Pabst und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Ziel/Aim SFTs are rare mesenchymal tumors frequently diagnosed late due to delayed occurrence of symptoms. Localized tumors are mostly treated by resection, while there is no effective standard treatment for advanced, metastatic stages. Hence, accurate imaging is essential, especially due to detection limits of current imaging modalities. Therefore, we aim to assess accuracy and impact on management of Ga-68-FAPI-46 PET. Methodik/Methods 10 patients with advanced SFTs who received clinical Ga-68-FAPI-46 and F-18-FDG PET/CTs between July 2020 and February 2022 were enrolled in an observational study and retrospectively reviewed. For detection efficacy, two blinded nuclear medicine physicians and one radiologist performed a lesion-based analysis independently. Disagreement was resolved by joint consensus read. Standard of reference were conventional CT and/or clinical/imaging follow-up. A lesion-based analysis of SUV max /SUV mean was performed and Tumor-to-Background ratios (TBRs) (liver, blood pool, muscle) were compared using Wilcoxon-Test. Change in management was determined by questionnaires sent to the treating physician after imaging was performed. P
Zitieren
APA
Pabst, K., Fendler, W. P., Schaarschmidt, B. M., Kessler, L., Mavroeidi, I. A., Lanzafame, H., Bartel, T., Schildhaus, H. U., Hirmas, N., Bauer, S., Zarrad, F., Fragoso-Costa, P., Herrmann, K., Siveke, J. T., & Hamacher, R. (2023). Superiority of Ga-68-FAPI-46 over F-18-FDG PET/CT in patients with solitary fibrous tumors (SFT). Nuklearmedizin - NuclearMedicine, 62(02), 121-122. https://doi.org/10.1055/s-0043-1766254
Vancouver
Pabst K, Fendler WP, Schaarschmidt BM, Kessler L, Mavroeidi IA, Lanzafame H, et al. Superiority of Ga-68-FAPI-46 over F-18-FDG PET/CT in patients with solitary fibrous tumors (SFT). Nuklearmedizin - NuclearMedicine. 2023;62(02):121-122. doi:10.1055/s-0043-1766254
BibTeX
@article{Pabst2023,
author = {Pabst, K. and Fendler, W. P. and Schaarschmidt, B. M. and Kessler, L. and Mavroeidi, I. A. and Lanzafame, H. and Bartel, T. and Schildhaus, H. U. and Hirmas, N. and Bauer, S. and Zarrad, F. and Fragoso-Costa, P. and Herrmann, K. and Siveke, J. T. and Hamacher, R.},
title = {Superiority of Ga-68-FAPI-46 over F-18-FDG PET/CT in patients with solitary fibrous tumors (SFT)},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2023},
volume = {62},
number = {02},
pages = {121--122},
doi = {10.1055/s-0043-1766254}
}
EUVIMED